KYMR Kymera Therapeutics

Kymera Therapeutics to Participate in Upcoming September Conferences

Kymera Therapeutics to Participate in Upcoming September Conferences

WATERTOWN, Mass., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, announced that Nello Mainolfi, PhD, Co-Founder, President and CEO, will participate in Fireside Chats at the following upcoming investor conferences:

  • 2022 Wells Fargo Healthcare Conference: September 7th at 1:20 p.m. ET
  • Morgan Stanley 20th Annual Global Healthcare Conference: September 14th at 8:00 a.m. ET
  • 2022 Guggenheim Nantucket Therapeutics Conference: September 28th at 2:15 p.m. ET

Presentation webcasts will be available under "Events and Presentations" in the Investors section of the Company's website at Archived webcast replays will be available on the website for approximately 90 days.

About Kymera Therapeutics

Kymera is a biopharmaceutical company pioneering the field of targeted protein degradation, a transformative approach to address disease targets and pathways inaccessible with conventional therapeutics. Kymera’s Pegasus platform is a powerful drug discovery engine, advancing novel small molecule therapies candidates designed to harness the body’s innate protein recycling machinery to degrade dysregulated, disease-causing proteins. With a focus on undrugged nodes in validated pathways, Kymera is advancing a pipeline of novel therapeutic candidates designed to address the most intractable of pathways and provide new treatments for patients. Kymera’s initial programs target IRAK4, IRAKIMiD, and STAT3 within the IL-1R/TLR or JAK/STAT pathways, providing the opportunity to treat patients with a broad range of immune-inflammatory diseases, hematologic malignancies, and solid tumors. For more information, visit .

Investor Contact:

Bruce Jacobs

Chief Financial Officer



857-285-5300

Chris Brinzey

Managing Director, Westwicke



339-970-2843

Media Contact:

Todd Cooper

Senior Vice President, Corporate Affairs



857-285-5300



EN
29/08/2022

Underlying

KYMRKymera Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Kymera Therapeutics

 PRESS RELEASE
Free
KYMR Kymera Therapeu...

Kymera Therapeutics Announces Fourth Quarter and Full Year 2025 Financ...

Kymera Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update KT-621 (STAT6) BROADEN2 Phase 2b trial in atopic dermatitis (AD) ongoing, with data expected by mid-2027 KT-621 BREADTH Phase 2b trial in asthma ongoing, with data expected in late-2027 Initiated dosing in KT-579 (IRF5) Phase 1 healthy volunteer trial with data expected in 2H26 Dr. Neil Graham, experienced biopharma leader, appointed Chief Development Officer Well-capitalized with $1.6 billion in cash as of December 31, 2025, and runway into 2029 Company to hold video con...

19h / 29m 1 EN
 PRESS RELEASE
Free
KYMR Kymera Therapeu...

Kymera Therapeutics to Participate in Upcoming March Investor Conferen...

Kymera Therapeutics to Participate in Upcoming March Investor Conferences WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will participate in fireside chats at the following upcoming investor events:  TD Cowen 46th Annual Healthcare Conference in Boston, MA on March 3 at 9:10 a.m. ET;Leerink Partners Global Healthcare Conference in Miami, FL on March 10 at 11:20 a.m. ET; andBarclays 28th Annual Global ...

February 24, 2026 1 EN
 PRESS RELEASE
Free
KYMR Kymera Therapeu...

Kymera Therapeutics to Report Fourth Quarter and Full Year 2025 Financ...

Kymera Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 WATERTOWN, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will report fourth quarter and full year 2025 financial results on February 26, 2026. The Company will host a video conference call and webcast at 8:30 a.m. ET that day. To join the video call or view the livestreamed webcast, please register via , or visit “” in the Investors section o...

February 19, 2026 1 EN
 PRESS RELEASE
Free
KYMR Kymera Therapeu...

Kymera Therapeutics to Participate in Upcoming February Investor Confe...

Kymera Therapeutics to Participate in Upcoming February Investor Conferences WATERTOWN, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that the Company will participate in fireside chats at the following upcoming investor events:  Guggenheim Emerging Outlook: Biotech Summit 2026 in New York, NY on February 11 at 9:00 a.m. ET; andOppenheimer Virtual 36th Annual Healthcare Life Sciences Conference on February 26 at 2:00 p.m. ET. ...

February 4, 2026 1 EN
 PRESS RELEASE
Free
KYMR Kymera Therapeu...

Kymera Therapeutics Announces First Patient Dosed in BREADTH Phase 2b ...

Kymera Therapeutics Announces First Patient Dosed in BREADTH Phase 2b Asthma Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader Data from the BREADTH Phase 2b asthma trial is expected to be reported in late-2027 Data from the ongoing parallel BROADEN2 Phase 2b atopic dermatitis trial is expected to be reported by mid-2027 WATERTOWN, Mass., Jan. 29, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that it recently initiated dosing i...

January 29, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch